{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:02:21Z","timestamp":1769558541532,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33530-5","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:33:31Z","timestamp":1769510011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploration of real-world outcomes in patients with previously treated HR+\/HER2- and triple negative metastatic breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Natalia","family":"Sadetsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetria","family":"Smith-Gaziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Natanzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliki","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"33530_CR1","unstructured":"Breast Cancer Facts & Figures 2024\u20132025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/2024\/breast-cancer-facts-and-figures-2024.pdf (2024)."},{"key":"33530_CR2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"33530_CR3","first-page":"dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J. Natl. Cancer Instit. 106, dju055 (2014).","journal-title":"JNCI J. Natl. Cancer Instit."},{"key":"33530_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.hoc.2013.05.003","volume":"27","author":"CK Anders","year":"2013","unstructured":"Anders, C. K., Zagar, T. M. & Carey, L. A. The management of early-stage and metastatic triple-negative breast cancer. Hematol. Oncol. Clin. North Am. 27, 737\u2013749 (2013).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"33530_CR5","doi-asserted-by":"publisher","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","volume":"95","author":"ML Plasilova","year":"2016","unstructured":"Plasilova, M. L. et al. Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine 95, e4614 (2016).","journal-title":"Medicine"},{"key":"33530_CR6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/curroncol28030209","volume":"28","author":"CP Amaro","year":"2021","unstructured":"Amaro, C. P., Batra, A. & Lupichuk, S. First-line treatment with a cyclin-dependent kinase 4\/6 inhibitor plus an aromatase inhibitor for metastatic breast cancer in Alberta. Curr. Oncol. 28, 2270\u20132280 (2021).","journal-title":"Curr. Oncol."},{"key":"33530_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/cells8040321","volume":"8","author":"N Sobhani","year":"2019","unstructured":"Sobhani, N. et al. Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer. Cells 8, 321 (2019).","journal-title":"Cells"},{"key":"33530_CR8","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-18-1161","volume":"19","author":"PJ Roberts","year":"2020","unstructured":"Roberts, P. J., Kumarasamy, V., Witkiewicz, A. K. & Knudsen, E. S. Chemotherapy and CDK4\/6 inhibitors: Unexpected bedfellows. Mol. Cancer Ther. 19, 1575\u20131588 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"33530_CR9","unstructured":"21st Century Cures Act. (2016)."},{"key":"33530_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/cpt.2800","volume":"113","author":"D Merola","year":"2023","unstructured":"Merola, D. et al. The Aetion coalition to advance real-world evidence through randomized controlled trial emulation initiative: Oncology. Clin. Pharmacol. Ther. 113, 1217\u20131222 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"33530_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","volume":"143","author":"JM Franklin","year":"2021","unstructured":"Franklin, J. M. et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: First results from the RCT DUPLICATE initiative. Circulation 143, 1002\u20131013 (2021).","journal-title":"Circulation"},{"key":"33530_CR12","doi-asserted-by":"publisher","unstructured":"Stewart, M. et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non\u2013small-cell lung cancer. JCO Clin. Cancer Inf. 1\u201315 (2019) https:\/\/doi.org\/10.1200\/CCI.18.00155.","DOI":"10.1200\/CCI.18.00155"},{"key":"33530_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cpt.2453","volume":"111","author":"DR Rivera","year":"2022","unstructured":"Rivera, D. R. et al. The friends of cancer research real-world data collaboration pilot 2.0: Methodological recommendations from oncology case studies. Clin. Pharmacol. Ther. 111, 283\u2013292 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"33530_CR14","doi-asserted-by":"publisher","first-page":"e2400091","DOI":"10.1200\/CCI.24.00091","volume":"8","author":"BA McKelvey","year":"2024","unstructured":"McKelvey, B. A. et al. Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy. JCO Clin. Cancer Inf. 8, e2400091. https:\/\/doi.org\/10.1200\/CCI.24.00091 (2024).","journal-title":"JCO Clin. Cancer Inf."},{"key":"33530_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X. et al. Breast cancer: Pathogenesis and treatments. Signal Transduct. Target. Ther. 10, 49 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"33530_CR16","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s12325-025-03201-y","volume":"42","author":"S Khozin","year":"2025","unstructured":"Khozin, S. et al. Real-world evidence acceptability and use in breast cancer treatment decision-making in the United States: Call-to-action from a multidisciplinary think tank. Adv. Ther. 42, 2973\u20132987 (2025).","journal-title":"Adv. Ther."},{"key":"33530_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/03007995.2021.1923468","volume":"37","author":"G Cuyun Carter","year":"2021","unstructured":"Cuyun Carter, G. et al. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer. Curr. Med. Res. Opin. 37, 1179\u20131187 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"33530_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clbc.2022.05.002","volume":"22","author":"D Patt","year":"2022","unstructured":"Patt, D. et al. Real-world treatment patterns and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer: Flatiron database analysis. Clin. Breast Cancer 22, 601\u2013610 (2022).","journal-title":"Clin. Breast Cancer"},{"key":"33530_CR19","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo, H. S. et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open 10, 104103 (2025).","journal-title":"ESMO Open"},{"key":"33530_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2217\/cer-2019-0077","volume":"8","author":"P Luhn","year":"2019","unstructured":"Luhn, P. et al. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. J. Comp. Eff. Res. 8, 1173\u20131185 (2019).","journal-title":"J. Comp. Eff. Res."},{"key":"33530_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/OP.24.00242","volume":"21","author":"S Alaklabi","year":"2025","unstructured":"Alaklabi, S. et al. Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer. JCO Oncol. Pract. 21, 620\u2013628 (2025).","journal-title":"JCO Oncol. Pract."},{"key":"33530_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ (Clinical Research ed.) 335, 806\u2013808 (2007).","journal-title":"BMJ (Clinical Research ed.)"},{"key":"33530_CR23","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"33530_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12885-017-3492-1","volume":"17","author":"T Decker","year":"2017","unstructured":"Decker, T. et al. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). BMC Cancer 17, 499 (2017).","journal-title":"BMC Cancer"},{"key":"33530_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33530_CR26","doi-asserted-by":"publisher","first-page":"S576","DOI":"10.1016\/j.jval.2024.10.3581","volume":"27","author":"L Slipski","year":"2024","unstructured":"Slipski, L., Dub, B., Yu, Y., Walker, M. & Natanzon, Y. RWD23 addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR)\u2014Focused real-world data (RWD). Value Health 27, S576 (2024).","journal-title":"Value Health"},{"key":"33530_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","volume":"99","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin. Pharmacol. Ther. 99, 325\u2013332 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"33530_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 11). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"33530_CR29","doi-asserted-by":"publisher","first-page":"175883592098765","DOI":"10.1177\/1758835920987651","volume":"13","author":"R Palumbo","year":"2021","unstructured":"Palumbo, R. et al. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive\/HER2 receptor-negative metastatic breast cancer: A real-world multicentre Italian study. Ther. Adv. Med. Oncol. 13, 1758835920987651 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"33530_CR30","doi-asserted-by":"publisher","first-page":"e0227256","DOI":"10.1371\/journal.pone.0227256","volume":"15","author":"C Huang Bartlett","year":"2020","unstructured":"Huang Bartlett, C. et al. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE 15, e0227256 (2020).","journal-title":"PLoS ONE"},{"key":"33530_CR31","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ijc.33959","volume":"150","author":"MJ Ha","year":"2022","unstructured":"Ha, M. J. et al. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+\/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int. J. Cancer 150, 2025\u20132037 (2022).","journal-title":"Int. J. Cancer"},{"key":"33530_CR32","doi-asserted-by":"publisher","first-page":"117822342312032","DOI":"10.1177\/11782234231203292","volume":"17","author":"A Celik","year":"2023","unstructured":"Celik, A. et al. Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer. Breast Cancer Basic Clin. Res. 17, 11782234231203292 (2023).","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"33530_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CMAR.S150960","volume":"10","author":"RL Mahtani","year":"2018","unstructured":"Mahtani, R. L. et al. Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: A US community-based real-world analysis. Cancer Manag. Res. 10, 249\u2013256 (2018).","journal-title":"Cancer Manag. Res."},{"key":"33530_CR34","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent, R. A. et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 19, 2349\u20132359 (2023).","journal-title":"Future Oncol."},{"key":"33530_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2- low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33530_CR36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. The Lancet 402, 1423\u20131433 (2023).","journal-title":"The Lancet"},{"key":"33530_CR37","doi-asserted-by":"publisher","first-page":"105841","DOI":"10.1016\/j.esmoop.2025.105841","volume":"10","author":"SM Tolaney","year":"2025","unstructured":"Tolaney, S. M. et al. Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: A real-world study. ESMO Open 10, 105841 (2025).","journal-title":"ESMO Open"},{"key":"33530_CR38","doi-asserted-by":"publisher","first-page":"e2400814","DOI":"10.1200\/PO-24-00814","volume":"9","author":"S Yadav","year":"2025","unstructured":"Yadav, S. et al. Real-world germline BRCA testing, poly(ADP-ribose) polymerase inhibitor utilization, and survival outcomes in human epidermal growth factor receptor 2-negative metastatic breast cancer. JCO Precis. Oncol. 9, e2400814 (2025).","journal-title":"JCO Precis. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33530-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33530-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33530-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:33:34Z","timestamp":1769510014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33530-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33530"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33530-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N Sadetsky, L Nguyen, and A Taylor are full-time employees of Gilead Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Gilead Pharmaceuticals, plc. P Prince is a full-time employee of Aetion, Inc. and holds stock options in Aetion. H Latimer is a prior employee of Aetion Inc. Y Natanzon is a full-time employee of ConcertAI, and holds stock options in ConcertAI. P Advaani receives from Gilead, Agendia, Astra Zeneca-DSI, Caris Life Sciences, Seagen\/Pfizer, Atossa Therapeutics, Modulation Therapeutics, Biovica International, Loxo Lilly, Sermonix, Menarini Stemline, Elephas, and Puma, serves on the advisory board for Epic Sciences, Biovica International, Astra Zeneca, DSI, Hesian Labs, Elephas, Belay diagnostics, Merck, Astrin and Biosciences, and consults for GE Healthcare, AstraZeneca, MJH Lifesciences, Menarini Stemline, Iksuda Therapeutics, Breathe Biomedical, Guardant Health, and DSI. D. Smith-Gaziani is grant funded by Bristol Myers Squibb Foundation. N. Freemantle has received funding for consulting from Gilead, Sanofi Aventis, ALK Abello, Orion, Argenx. P. Kaufman has stock and other ownership interests from Amgen and Johnson&Johnson, has received honoraria from Lilly, Eisai, AstraZeneca, Sermonix Pharmaceuticals, and Genentech\/Roche, has consulted for Polyphor, Genentech\/Roche, Eisai, Lilly, Pfizer, Merck, AstraZeneca, Seagen, Sermonix Pharmaceuticals, and Gilead, and has received research funding from Eisai, Polyphor, Lilly, Novartis, Pfizer, Sanofi, Zymeworks, and Sermonix Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"3613"}}